- $2.05bn
- $1.53bn
- $6.94m
U.S. STOCKS ON THE MOVE-Brystol Myers, Nvidia
U.S. STOCKS ON THE MOVE-Vanda Pharma, Tesla, Zillow
U.S. STOCKS ON THE MOVE-Micron Technology, Carvana, ServiceNow
Immunome rises after positive data from experimental tumor treatment
Immunome's experimental drug meets main goal in late-stage study (updated)
Brief: Immunome Announces Positive Topline Results From Phase 3 Ringside Trial Of Varegacestat In Patients With Desmoid Tumors
Immunome's experimental drug meets main goal in late-stage study
Immunome Q3 net loss widens, expects current cash to fund operations into 2027
Brief: Immunome Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Infinimmune Announces Research Collaboration With Immunome
Barclays cuts Merck to 'equal weight', cites multiple risks ahead of CMD
Immunome Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Immunome Reports Inducement Grants Under Nasdaq Listing Rule
Immunome Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Immunome Q1 Income From Operations USD -44.636 Million
Brief: Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Immunome doses first patient in early-stage trial of its experimental cancer treatment
U.S. STOCKS ON THE MOVE-Brunswick, Carpenter Technology, Dover